首页> 外国专利> escitaloproma free base, pharmaceutical composition, process for making escitaloprama free base or a salt thereof, crystalline escitaloprama base or an escitaloprama oxalate salt, processes for making an escitaloprama salt and reducing the amount of escitaloprama, n-oxide on escitaloprama free base or a salt thereof, orodispersible tablet, and method of manufacturing an orodispersible tablet

escitaloproma free base, pharmaceutical composition, process for making escitaloprama free base or a salt thereof, crystalline escitaloprama base or an escitaloprama oxalate salt, processes for making an escitaloprama salt and reducing the amount of escitaloprama, n-oxide on escitaloprama free base or a salt thereof, orodispersible tablet, and method of manufacturing an orodispersible tablet

机译：escitaloproma游离碱，药物组合物，escitaloprama游离碱或其盐的制备方法，结晶escitaloprama碱或escitaloprama草酸盐的制备方法，escitaloprama盐的制备方法和减少escitaloprama的盐，escitaloprama游离碱或盐的氧化物其，口腔分散片剂和制造口腔分散片剂的方法

页面导航

摘要
著录项
相似文献

摘要

SCITALOPRAM FREE BASE, PHARMACEUTICAL COMPOSITION, PROCESS FOR MANUFACTURING SCITALOPRAM FREE BASE OR A SALT, SCYSTALOPRAM CRYSTALLINE BASE OR A SCITALOPRAM OXALATE SALT FOR FABRATIC BALANCE OF SCYTHALOPRAM, N-oxide based on SCITALOPRAM-FREE OR A SALT OF THE SAME, ORODISPERSIBLE TABLET, AND METHOD OF MANUFACTURE OF A ORODISPERSIBLE TABLET The present invention relates to the crystalline base of the well-known escitaloprarna antidepressant drug - S-1 3- (dimethylamino) propyl] -1- (4-fluorophenyl) -1,3-dihydro-5-isobenzofuranocarbonitrile formulations of said base, a process for the preparation of purified escitaloprama salts, such as oxalate, using base, salts obtained by said process and formulations containing said salts, and a process for the preparation of purified escitaloprama free base or escitaloprama salts, such as oxalate, using hydrobromide, salts obtained by said process and formulations containing said salts are provided. Finally, the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral disintegration time of less than 120 s and comprising a pharmaceutical active ingredient adsorbed on a water-soluble filler wherein the pharmaceutical active ingredient has a melting point in the range 40-1000 ° C, and also a method for preparing an orodispersible tablet of the said type.

机译：SCITALOPRAM游离碱，药物组合物，制造SCITALOPRAM游离碱或盐的过程，SCYSTALOPRAM结晶碱或SCITALOPRAM草酸盐用于在STALTALOPRAM上进行精确平衡，基于STAL或无糖的S，STAL或无糖可食性片剂的制造方法本发明涉及众所周知的escitaloprarna抗抑郁药-S-1 3-（二甲氨基）丙基] -1-（4-氟苯基）-1，3-二氢-5的结晶基质。所述碱的-异苯并呋喃甲腈制剂，使用碱制备纯化的依地普仑盐，例如草酸盐的方法，通过所述方法获得的盐和含有所述盐的制剂，以及制备纯化的依地普仑游离碱或依地普尔盐的方法，使用氢溴酸盐，例如草酸盐，提供通过所述方法获得的盐和含有所述盐的制剂。最后，本发明涉及一种口腔分散片剂，其具有至少22N的硬度和小于120s的口腔崩解时间，并且包含吸附在水溶性填充剂上的药物活性成分，其中所述药物活性成分具有熔点在40-1000℃的温度范围内，以及制备所述类型的口腔分散片剂的方法。

著录项

公开/公告号BRPI0612295A2

专利类型
公开/公告日2011-01-04

原文格式PDF
申请/专利权人 H. LUNDBECK A / S;
展开▼

申请/专利号BR2006PI12295
发明设计人 ROBERT DANCER;HANS PETERSEN;OLE NIELSEN;MICHAEL HAROLD ROCK;HELLE ELIASEN;KEN LILJEGREN;
展开▼

申请日2006-06-22
分类号C07D307/87;
国家 BR
入库时间 2022-08-21 18:07:15

相似文献

专利
外文文献
中文文献